Nothing Special   »   [go: up one dir, main page]

Liu et al., 2022 - Google Patents

Experimental therapy of HER2-expressing xenografts using the second-generation HER2-targeting affibody molecule 188Re-ZHER2: 41071

Liu et al., 2022

View HTML
Document ID
13081463053501985342
Author
Liu Y
Vorobyeva A
Orlova A
Konijnenberg M
Xu T
Bragina O
Loftenius A
Rosander E
Frejd F
Tolmachev V
Publication year
Publication venue
Pharmaceutics

External Links

Snippet

HER2-targeted radionuclide therapy might be helpful for the treatment of breast, gastric, and ovarian cancers which have developed resistance to antibody and antibody-drug conjugate- based therapies despite preserved high HER2-expression. Affibody molecules are small …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Similar Documents

Publication Publication Date Title
Hennrich et al. [68Ga] Ga-DOTA-TOC: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging
Allen et al. Comparative radioimmunotherapy of experimental melanoma with novel humanized antibody to melanin labeled with 213Bismuth and 177Lutetium
Huynh et al. Copper-67-labeled bombesin peptide for targeted radionuclide therapy of prostate cancer
Bell et al. Glypican-3-targeted alpha particle therapy for hepatocellular carcinoma
Vorobyeva et al. Feasibility of imaging EpCAM expression in ovarian cancer using radiolabeled DARPin Ec1
Dahlsson Leitao et al. Molecular design of HER3-targeting affibody molecules: Influence of chelator and presence of HEHEHE-tag on biodistribution of 68Ga-labeled tracers
Stenberg et al. Evaluation of the PSMA-binding ligand 212Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer
Oroujeni et al. Preclinical evaluation of 99mTc-ZHER2: 41071, a second-generation affibody-based HER2-Visualizing imaging probe with a low renal uptake
Liu et al. Experimental therapy of HER2-expressing xenografts using the second-generation HER2-targeting affibody molecule 188Re-ZHER2: 41071
Vorobyeva et al. Radionuclide molecular imaging of EpCAM expression in triple-negative breast cancer using the scaffold protein DARPin Ec1
Garousi et al. Influence of several compounds and drugs on the renal uptake of radiolabeled affibody molecules
Sugyo et al. Efficacy evaluation of combination treatment using gemcitabine and radioimmunotherapy with 90Y-labeled fully human anti-CD147 monoclonal antibody 059-053 in a BxPC-3 xenograft mouse model of refractory pancreatic cancer
Wharton et al. Preclinical Evaluation of [155/161Tb] Tb-Crown-TATE—A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours
Liu et al. Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain
Deyev et al. Influence of the position and composition of radiometals and radioiodine labels on imaging of Epcam expression in prostate cancer model using the DARPin Ec1
Majkowska-Pilip et al. Application of neurokinin-1 receptor in targeted strategies for glioma treatment. Part I: Synthesis and evaluation of substance P fragments labeled with 99mTc and 177Lu as potential receptor radiopharmaceuticals
Oroujeni et al. Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3
Tolmachev et al. Direct in vivo comparison of 99mTc-labeled scaffold proteins, DARPin G3 and ADAPT6, for visualization of HER2 expression and monitoring of early response for trastuzumab therapy
Oroujeni et al. The Use of a Non-Conventional Long-Lived Gallium Radioisotope 66Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR: 2377 Affibody Molecule
Lundmark et al. Preclinical characterisation of PSMA/GRPR-targeting heterodimer [68Ga] Ga-BQ7812 for PET diagnostic imaging of prostate cancer: A step towards clinical translation
Miederer et al. Alpha-emitting radionuclides: current status and future perspectives
Rinne et al. Benefit of later-time-point PET imaging of HER3 expression using optimized radiocobalt-labeled affibody molecules
Rinne et al. HER3 pet imaging: 68Ga-labeled affibody molecules provide superior HER3 contrast to 89Zr-labeled antibody and antibody-fragment-based tracers
Lo et al. Molecular imaging and preclinical studies of radiolabeled long-term RGD peptides in U-87 MG tumor-bearing mice
Maurin et al. [99mTc] Tc-PSMA-T4—Novel SPECT Tracer for Metastatic PCa: From Bench to Clinic